Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.47 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 3/20 | 0.46 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.46 |
| ▸ | CHRM2 known ✓ | P08172 | 1/20 | 0.46 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.46 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.46 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.46 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.46 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.46 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26621753 | 0.98 | KEAP1 (0.60) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 | |
| SCHEMBL11065 | 0.98 | KEAP1 (0.60) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 | |
| Hydrochloric Acid SCHEMBL23116183 | 0.93 | KEAP1 (0.56) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 | |
| SCHEMBL2746864 | 0.91 | KEAP1 (0.58) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 | |
| SCHEMBL11536090 | 0.88 | SMN1; SMN2 (0.56) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 | |
| Hydrochloric Acid SCHEMBL9703482 | 0.85 | ALDH1A1 (0.50) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 | |
| Hydrochloric Acid SCHEMBL11275 | 0.85 | ALDH1A1 (0.50) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 | |
| Bicarbonate SCHEMBL28180070 | 0.84 | LMNA (0.49) | KEAP1SMN1; SMN2MAPK1LMNAHPGD | |
| Hydrochloric Acid SCHEMBL28756894 | 0.83 | GLA (0.48) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 | |
| SCHEMBL8997786 | 0.82 | KEAP1 (0.46) | KEAP1SMN1; SMN2MAPK1LMNAUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 332 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120157674-A | New preparation method of domperidone | 刘辉 | 2025-06-17 | — | — | CN | claimed |
| EP-2409704-A2 | c-Met modulators and methods of use | Exelixis Inc. (US) | 2012-01-25 | — | — | EP | claimed |
| CN-101402610-A | Synthesis method of 4-(3-chlorine-4-fluorobenzene amino)-7-methoxy-6-[3-(4-morpholinyl)-propoxy] quinoline | ZHEJIANG EXCEL PHARMACEUTICAL (CN) | 2009-04-08 | — | — | CN | claimed |
| EP-4673439-A1 | STING AGONISTS CONTAINING HYDRAZIDE, HYDRAZINE, AND HYDROXAMIC ACID FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| EP-4673445-A1 | STING AGONISTS CONTAINING BENZYLIC ALCOHOL AND BENZYLIC AMINE FUNCTIONAL GROUPS | BioNTech SE (DE) | 2026-01-07 | — | — | EP | disclosed |
| CN-120157674-A | New preparation method of domperidone | 刘辉 | 2025-06-17 | — | — | CN | disclosed |
| CN-120157674-A | New preparation method of domperidone | 刘辉 | 2025-06-17 | — | — | CN | disclosed |
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | PFIZER INC. (US) | 2025-05-13 | — | — | US | disclosed |
| CN-119431355-A | Phenyl thiazole derivative, composition and application thereof | 徐州医科大学 | 2025-02-14 | — | — | CN | disclosed |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | LOMOND THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-4518603-A | ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1985-05-21 | — | — | US | disclosed |
| US-4495183-A | ANTIULCER AGENTS- GASTROLINTESTINAL DISORDERS | A. H. ROBINS COMPANY, INCORPORATED (US) | 1985-01-22 | — | — | US | disclosed |
| US-4480100-A | CHEMICAL INTERMEDIATES FOR ANTIDEPRESSANTS | A. H. ROBINS COMPANY, INC. (US) | 1984-10-30 | — | — | US | disclosed |
| US-4447361-A | ANTIDEPRESSANT | A. H. ROBINS COMPANY, INC. (US) | 1984-05-08 | — | — | US | disclosed |
| EP-0107261-A2 | (2-((Nitropyridinyl)amino)phenyl)arylmethanones and salts, their use in medicine, pharmaceutical compositions containing them and their use in the preparation of (2-((aminopyridinyl)amino)phenyl)arylmethanones and pyrido(1,4)benzodiazepines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-05-02 | — | — | EP | disclosed |
| EP-0099614-A2 | Nitro, amino and aroylamino-N-phenylpyridinamines and their use in a process for preparing pyrido(1,4)benzodiazapines | A.H. ROBINS COMPANY, INCORPORATED (US) | 1984-02-01 | — | — | EP | disclosed |
| EP-0076017-A2 | Phenyl substituted pyrido(1,4)benzodiazepines and intermediates therefor | A.H. ROBINS COMPANY, INCORPORATED (US) | 1983-04-06 | — | — | EP | disclosed |
| US-4230850-A | HYPOTENSIVE AGENTS, VASODILATION | LIPHA, LYONNAISE INDUSTRIELLE PHARMACEUTIQUE (FR) | 1980-10-28 | — | — | US | disclosed |
| US-4094870-A | 2-Substituted thio-1,4-benzodiazepine derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JA) | 1978-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297190-B2 | Modulators of STING (stimulator of interferon genes) | STING1, IRF3, CGAS | GLA 1538/4885HRH3 2049/4885SIGMAR1 2484/4885 |
| US-20250011319-A1 | SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF | FLT3, PDXK, PHKG1 | GLA 4296/4885HRH3 305/4885SIGMAR1 3637/4885 |
| US-12091425-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | GLA 2956/4885HRH3 4640/4885SIGMAR1 4041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.